Phase II trial of weekly gemcitabine and docetaxel combination therapy for relapsed ovarian or peritoneal cancer

Trial Profile

Phase II trial of weekly gemcitabine and docetaxel combination therapy for relapsed ovarian or peritoneal cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Docetaxel (Primary) ; Gemcitabine (Primary)
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 16 Mar 2016 Status changed from completed to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 08 Feb 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top